title: Personalized cancer vaccines: Targeting the cancer mutanome.
abstract: The development of next generation sequencing technologies has revolutionized our understanding of how specific genetic events contribute to cancer initiation and progression. Dramatic improvements in instrument design and efficiency, combined with significant cost reductions has permitted a systematic analysis of the mutational landscape in a variety of cancer types. At the same time, a detailed map of the cancer mutanome in individual cancers offers a unique opportunity to develop personalized cancer vaccine strategies targeting neoantigens. Recent studies in both preclinical models and human cancer patients demonstrate that neoantigens (1) are important targets following checkpoint inhibition therapy, (2) have been identified as the target of adoptive T cell therapies, and (3) can be successfully targeted with personalized vaccines. Taken together, these observations provide strong rationale for the clinical translation of personalized cancer vaccines.
authors.affiliation: Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, United States.
authors.forename: Xiuli
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, United States.
authors.forename: Piyush K
authors.initials: PK
authors.lastname: Sharma
authors.affiliation: Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, United States; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, United States.
authors.forename: S
authors.initials: S
authors.lastname: Peter Goedegebuure
authors.affiliation: Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, United States; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, United States. Electronic address: gillandersw@wudosis.wustl.edu.
authors.forename: William E
authors.initials: WE
authors.lastname: Gillanders
mesh_terms: D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics; D002986:Clinical Trials as Topic; D005822:Genetic Vectors / Q000737:chemistry / Q000378:metabolism; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D058990:Molecular Targeted Therapy; D009154:Mutation; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology / Q000627:therapeutic use; D057285:Precision Medicine / Q000295:instrumentation / Q000379:methods*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology; D019444:Vaccines, DNA / Q000096:biosynthesis / Q000235:genetics / Q000627:therapeutic use
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D010455:Peptides; D011948:Receptors, Antigen, T-Cell; D019444:Vaccines, DNA
keywords: Cancer vaccine; Genome sequencing; Neoantigen; Personalized